desethyloxybutynin: metabolite of oxybutynin; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 133577 |
| CHEMBL ID | 3544785 |
| CHEBI ID | 174441 |
| SCHEMBL ID | 3364411 |
| MeSH ID | M0101842 |
| Synonym |
|---|
| desethyloxybutynin |
| unii-8809snk4f7 |
| 8809snk4f7 , |
| benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(ethylamino)-2-butynyl ester |
| CHEBI:174441 |
| n-desethyloxybutynin |
| 4-(ethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate |
| 80976-67-6 |
| deethyloxybutynin |
| SCHEMBL3364411 |
| 4-ethylamino-2-butynyl cyclohexylphenyl-glycolate |
| SNIBJKHIKIIGPR-UHFFFAOYSA-N |
| 4-(ethylamino)-2-butynyl alpha-cyclohexyl-alpha-hydroxybenzeneacetate |
| n-desethyloxybutynin, (+/-)- |
| benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, 4-(ethylamino)-2-butyn-1-yl ester |
| nt0502 |
| nt-0502 |
| nrx-101 |
| CHEMBL3544785 |
| Q27269871 |
| DTXSID701001668 |
| 4-(ethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate |
| benzeneacetic acid, a-cyclohexyl-a-hydroxy-, 4-(ethylamino)-2-butynylester, (as)- |
| (r,s) - desethyl oxybutynin |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The safety was measured by recording adverse events on questionnaires." | ( Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Hakonen, T; Lehtoranta, K; Lukkari-Lax, E; Tainio, H; Tammela, TL, 2002) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " A trend of increasing peak plasma levels and bioavailability was observed with increasing age and frailty, with the differences more apparent between the active elderly and frail elderly groups than between the active elderly and young volunteers." | ( Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Geraint, M; Gordon, D; Hughes, KM; Lang, JC; Lazare, R; Malone-Lee, J; Stanton, SL, 1992) | 0.28 |
| "The effect of time interval between food and drug ingestion on the bioavailability of oxybutynin was investigated in a randomized, three-phase cross-over study in 31 healthy volunteers." | ( Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. Aranko, K; Hakonen, T; Juhakoski, A; Lukkari, E; Neuvonen, PJ, 1997) | 0.3 |
| "Oxybutynin has low oral bioavailability due to an extensive presystemic metabolism." | ( Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Aranko, K; Juhakoski, A; Lukkari, E; Neuvonen, PJ, 1997) | 0.3 |
| " With OROS oxybutynin chloride, mean relative bioavailability was higher (153%) for oxybutynin and lower (69%) for N-desethyloxybutynin compared with IR oxybutynin." | ( Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. Gupta, SK; Sathyan, G, 1999) | 0.51 |
| "In four phase I studies, we separately assessed the effects of OTG application site selection on oxybutynin bioavailability (site-to-site study); the effects of post-application showering on oxybutynin steady-state pharmacokinetics (showering study); the effects of sunscreen application on oxybutynin absorption (sunscreen study); and the person-to-person transfer of oxybutynin through skin-to-skin contact at the application site (transference study)." | ( Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Caramelli, KE; Dmochowski, RR; Hoel, G; Newman, DK; Rudy, DC; Sand, PK; Thomas, H, 2011) | 0.37 |
| "The bioavailability of oxybutynin and its pharmacokinetic profile are not greatly affected by application site selection, post-application showering or sunscreen use shortly before or after dosing with OTG." | ( Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Caramelli, KE; Dmochowski, RR; Hoel, G; Newman, DK; Rudy, DC; Sand, PK; Thomas, H, 2011) | 0.37 |
| " Bioavailability of the more active (R)-enantiomer was 7% for oral and 10%-22% for intravesical administration." | ( A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers. Albrecht, U; Fuhr, U; Krause, P; Kretschmar, M; Rubenwolf, P; Stein, R; Suleiman, AA; Taubert, M, 2021) | 0.62 |
Oxybutynin and its main active metabolite, N-desethyloxy butynin, are reached 24 - 48 hours after a single application. therapeutic concentrations are maintained throughout the dosage interval.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The short half-life of oxybutynin administered as a conventional tablet formulation or syrup requires 2-3 times daily dosage to be effective." | ( Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Haarala, M; Hakonen, T; Kiilholma, P; Kivelä, A; Lukkari, E; Nilsson, CG, 1997) | 0.3 |
| "To determine the pharmacokinetics of oxybutynin and its main active metabolite, N-desethyloxybutynin, after multiple dosage (5 mg/30 ml three times daily) of intravesical oxybutynin formulation." | ( Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Hakonen, T; Lehtoranta, K; Lukkari-Lax, E; Tainio, H; Tammela, TL, 2002) | 0.54 |
| " Peak plasma concentrations of oxybutynin and the major active metabolite, N-desethyloxybutynin, are reached 24 - 48 hours after a single application and therapeutic concentrations are maintained throughout the dosage interval." | ( Transdermal oxybutynin: for overactive bladder. Bang, LM; Easthope, SE; Perry, CM, 2003) | 0.55 |
| " Moreover, oxybutynin ER offers greater flexibility in dosage (5-30 mg/day) than the other available treatment options." | ( Oxybutynin extended-release: a review of its use in the management of overactive bladder. Perry, CM; Scott, LJ; Siddiqui, MA, 2004) | 0.32 |
| " Although the suppression induced by solifenacin was more persistent than that due to oxybutynin, the antagonistic effect of solifenacin on the dose-response curves to pilocarpine was significantly weaker than that of oxybutynin." | ( Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Miyata, K; Oki, T; Sato, S; Yamada, S, 2005) | 0.33 |
| "The bioavailability of oxybutynin and its pharmacokinetic profile are not greatly affected by application site selection, post-application showering or sunscreen use shortly before or after dosing with OTG." | ( Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Caramelli, KE; Dmochowski, RR; Hoel, G; Newman, DK; Rudy, DC; Sand, PK; Thomas, H, 2011) | 0.37 |
| Class | Description |
|---|---|
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 8 (21.05) | 18.2507 |
| 2000's | 23 (60.53) | 29.6817 |
| 2010's | 5 (13.16) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 12 (31.58%) | 5.53% |
| Reviews | 1 (2.63%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 25 (65.79%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||